Drugs such as Wegovy mimic the actions of glucagon-like peptide-1 (GLP-1), a hormone secreted by the gastrointestinal tract, and are referred to as GLP-1 agonists facilitate weight loss by stimulating insulin secretion, delaying the emptying of the stomach contents, and reducing hunger
Key challenges include compartment specific release of the formulation, controlling the release kinetics and the co-localization of the peptide with the functional excipients at the epithelial wall (Maher and Brayden, 2021)
Injection should not be made into a muscle (intramuscularly) or into a vein (intravenously)
These findings support the concept that glucagon receptor activation may be therapeutically useful when balanced by GLP-1 receptor signaling, although retatrutide currently provides the most prominent evidence for triple receptor agonism
For body recomposition specifically, Retatrutide addresses the fat loss side of the equation with unprecedented effectiveness